Barclays Increases Pfizer Price Targe

In a report released Wednesday, Barclays analyst Mark Purcell increases his price target for Pfizer

from $32 to $34 a share, maintaining a EW rating on the drug maker. Analyst at Barclays are more bullish on the pharmaceutical sector and favors Pfizer's potential for organic growth. Purcell mentions Pfizer's near term potential depends on the company's ability to change its tax structure, increase transactions through core operations, and increase its pipeline to full potential.